Insulin therapy and body weight: benefits of biphasic human insulin analogue NovoMix 30

Body weight (BW) excess is a characteristic problem for type 2 diabetes mellitus (T2DM) both as its pathogenetic feature and as a side effect of blood glucose lowering therapy. In the latter case reduction of glycosuria and frequent hypoglycemic events are primarily blamed for BW gain, but additiona...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Elena Viktorovna Surkova
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2013
Materias:	insulin therapy body weight novomix 30 Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/f7819690429c457ab589d052cfd31b4b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f7819690429c457ab589d052cfd31b4b
record_format	dspace
spelling	oai:doaj.org-article:f7819690429c457ab589d052cfd31b4b2021-11-14T09:00:18ZInsulin therapy and body weight: benefits of biphasic human insulin analogue NovoMix 302072-03512072-037810.14341/2072-0351-3597https://doaj.org/article/f7819690429c457ab589d052cfd31b4b2013-03-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/3597https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Body weight (BW) excess is a characteristic problem for type 2 diabetes mellitus (T2DM) both as its pathogenetic feature and as a side effect of blood glucose lowering therapy. In the latter case reduction of glycosuria and frequent hypoglycemic events are primarily blamed for BW gain, but additional factors like direct effect of insulin on lipogenesis and influence of its supraphysiologic levels on regulation of appetite via CNS structures are also under discussion.Advances of the last years have brought new hope due to introduction of drug classes that do not affect BW. However, fraction of patients dependent on exogenous insulin shows stable trend for growth. Deterioration of beta-cell secretory capacity makes insulin an ultimately indispensable tool in the foreseeable future. As so, insulin therapy modalities with minimal impact on BW are preferable. In this regard human insulin analogues of both rapid and prolonged action have certain advantages.Current article addresses influence of pre-mixed insulin preparation NovoMix 30 (Novo Nordisk, Denmark) on BW. A summary of several studies of substantial duration (up to 3 years) suggests a neutral effect on BW in various categories of T2DM patients (including obese and elder patients).Therapy with pre-mixed preparations is an adequately safe and effective T2DM treatment modality and is advantageous for patients in whom BW gain is particularly unfavorable.Elena Viktorovna SurkovaEndocrinology Research Centrearticleinsulin therapybody weightnovomix 30Nutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 16, Iss 1, Pp 52-56 (2013)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	insulin therapy body weight novomix 30 Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	insulin therapy body weight novomix 30 Nutritional diseases. Deficiency diseases RC620-627 Elena Viktorovna Surkova Insulin therapy and body weight: benefits of biphasic human insulin analogue NovoMix 30
description	Body weight (BW) excess is a characteristic problem for type 2 diabetes mellitus (T2DM) both as its pathogenetic feature and as a side effect of blood glucose lowering therapy. In the latter case reduction of glycosuria and frequent hypoglycemic events are primarily blamed for BW gain, but additional factors like direct effect of insulin on lipogenesis and influence of its supraphysiologic levels on regulation of appetite via CNS structures are also under discussion.Advances of the last years have brought new hope due to introduction of drug classes that do not affect BW. However, fraction of patients dependent on exogenous insulin shows stable trend for growth. Deterioration of beta-cell secretory capacity makes insulin an ultimately indispensable tool in the foreseeable future. As so, insulin therapy modalities with minimal impact on BW are preferable. In this regard human insulin analogues of both rapid and prolonged action have certain advantages.Current article addresses influence of pre-mixed insulin preparation NovoMix 30 (Novo Nordisk, Denmark) on BW. A summary of several studies of substantial duration (up to 3 years) suggests a neutral effect on BW in various categories of T2DM patients (including obese and elder patients).Therapy with pre-mixed preparations is an adequately safe and effective T2DM treatment modality and is advantageous for patients in whom BW gain is particularly unfavorable.
format	article
author	Elena Viktorovna Surkova
author_facet	Elena Viktorovna Surkova
author_sort	Elena Viktorovna Surkova
title	Insulin therapy and body weight: benefits of biphasic human insulin analogue NovoMix 30
title_short	Insulin therapy and body weight: benefits of biphasic human insulin analogue NovoMix 30
title_full	Insulin therapy and body weight: benefits of biphasic human insulin analogue NovoMix 30
title_fullStr	Insulin therapy and body weight: benefits of biphasic human insulin analogue NovoMix 30
title_full_unstemmed	Insulin therapy and body weight: benefits of biphasic human insulin analogue NovoMix 30
title_sort	insulin therapy and body weight: benefits of biphasic human insulin analogue novomix 30
publisher	Endocrinology Research Centre
publishDate	2013
url	https://doaj.org/article/f7819690429c457ab589d052cfd31b4b
work_keys_str_mv	AT elenaviktorovnasurkova insulintherapyandbodyweightbenefitsofbiphasichumaninsulinanaloguenovomix30
_version_	1718429625410912256

Insulin therapy and body weight: benefits of biphasic human insulin analogue NovoMix 30

Ejemplares similares